The U.S. Food and Drug Administration (FDA) has initiated a safety study on Mifepristone, the abortion pill, with the backing of the White House. This move comes amid ongoing legal challenges regarding the pill's distribution and use, particularly following a Supreme Court ruling that overturned Roe v. Wade. The FDA maintains that Mifepristone remains safe and effective when used as directed. The safety study will utilize existing drug safety systems and is expected to take approximately six months to complete. Preliminary results are anticipated by July 2024, while comprehensive findings may not be available until after the upcoming midterm elections in November 2024. Mifepristone, part of a two-drug regimen, is responsible for two-thirds of abortions in the U.S., and abortion rights advocates view the legal battles surrounding it as a critical threat to access. The FDA is also considering hiring a contractor to assist in gathering and analyzing data on the medication's use, aiming to ensure the study withstands any legal scrutiny.